A recent investigation of 67 FLT3-ITD+ AML patients who were treated with class I or II inhibitors demonstrated that more than half of the patients had detectable mutations at relapse, from which 26% had mutations in the TKD of FLT3 (D835). This evidence concerns the gene FLT3 and acute myeloid leukemia.